News

Filter

Current filters:

Eisai

1 to 9 of 887 results

Epizyme regains rights to cancer program from Eisai

Epizyme regains rights to cancer program from Eisai

13-03-2015

US clinical stage biotech firm Epizyme’s) shares rose 14.7% to $25.45 by close of trading on Thursday,…

BiotechnologyEisaiEpizymeEPZ-6438LicensingOncology

Eisai's Halaven to stay on UK Cancer Drugs Fund list pending reconsideration

Eisai's Halaven to stay on UK Cancer Drugs Fund list pending reconsideration

11-03-2015

Japanese drug major Eisai has announced that its drug Halaven (eribulin) will remain on the UK's National…

EisaiHalavenOncologyPharmaceuticalRegulationUK

Eisai and Merck enter cancer research collaboration

05-03-2015

Japanese drug major Eisai saw its shares gain 7.15% to 6,732 yen after it announced it had entered into…

EisaiHalavenKeytrudaLenvimaMerck & CoOncologyPharmaceuticalResearch

First launch for Eisai’s Lenvima, in the USA

First launch for Eisai’s Lenvima, in the USA

03-03-2015

The US subsidiary of Japanese pharma major Eisai has now launched its in-house developed novel anticancer…

EisailenvatinibLenvimaMarkets & MarketingOncologyPharmaceuticalRare diseases

UPDATE: FDA approves Eisai’s Lenvima for a type of thyroid cancer and expands use of Banzel

UPDATE: FDA approves Eisai’s Lenvima for a type of thyroid cancer and expands use of Banzel

14-02-2015

The US Food and Drug Administration on Friday granted approval for Japanese pharma major Eisai’s Lenvima…

BanzelEisailenvatinibLenvimaNeurologicalOncologyPharmaceuticalRare diseasesRegulationUSA

Eisai's lenvatinib shows statistically-significant progression-free survival in Ph III trial

Eisai's lenvatinib shows statistically-significant progression-free survival in Ph III trial

13-02-2015

Japanese drug major Eisai has published results of its SELECT Phase III study, showing its lenvatinib…

EisaiHealthJapanlenvatinibPharmaceuticalWeakness

Helsinn grants Stendhal rights to NEPA in several Latin America countries

02-02-2015

Family-run Swiss oncology specialist Helsinn has granted exclusive rights to Mexico-based Especificos…

AkynzeoEisaiHelsinnLicensingNEPAnetupitantOncologypalonosetronPharmaceuticalSouth AmericaStendhal

German Federal Joint Committee confirms 'considerable' benefit of Eisai's Halaven in breast cancer

German Federal Joint Committee confirms 'considerable' benefit of Eisai's Halaven in breast cancer

23-01-2015

The German Federal Joint Committee has confirmed the ‘considerable’ additional benefit of Japanese…

EisaiGermanyHalavenOncologyPharmaceuticalRegulation

1 to 9 of 887 results

Back to top